i t n ercutaneous coronary intervention (PCI) is frequently erformed in patients who received fibrinolytic therapy for cute myocardial infarction (MI). Currently, unfractionated eparin is the most commonly used antithrombin therapy in his situation. However, unfractionated heparin has certain imitations. It has a narrow therapeutic range, monitoring of he activated clotting time is required, an...

J. Schrader, MD, Department of Nephrology, University Hospital, Robert-Koch-Strasse 40, D-3400 Göttingen (FRG) Dear Sir, We read with interest the recent report of Ponce et al. [1] in this journal on the interference of heparin with peritoneal solute transport. It has shown that intraperitoneal application of standard heparin does not affect or only slightly affects systemic blood coagulation [...

Heparin is the predominant anticoagulant used in cardiac and vascular surgery. Heparin-induced thrombocytopenia (HIT) is one of the most serious and life-threatening adverse drug reactions associated with heparin use. In addition to the development of thrombocytopenia, HIT is associated with a high risk (40-50%) of thrombotic complications. The pathophysiology of HIT is now well understood and ...

Using the chromogenic substrate S-2222, we have optimized and automated an amidolytic assay for heparin. The assay is based on the detection of anti-Xa activity generated by heparin in plasma. The method is reproducible (intra- and interassay CVs of 2.4 and 3.3%, respectively) and reliable in antithrombin III-deficient plasma. Results of this assay, obtained for plasma samples from patients and...

The anticoagulant activity of heparin dissolved in intravenous solutions was measured by two different methods of heparin assay. Both procedures showed markedly reduced anticoagulant activity within four hours after the addition of heparin to the solutions. When measured according to the procedure of Yin, heparin in the intravenous solutions fully regained its lost anticoagulant activity after...

Aim of the study: to evaluate effect meglumine sodium succinate (MSS) on efficacy anticoagulant therapy in patients with severe COVID-19 infection complicated by bilateral community-acquired pneumonia. Materials and methods. Overall treatment was analyzed 12 hospitalized ICU diagnosis confirmed coronavirus (U07.1) multisegmental All received prophylactic anticoagulation unfractionated heparin. ...

Thrombin bound to a fibrin clot remains active and poorly accessible to heparin-AT III complex. During fibrinolysis, thrombin is released as thrombin-FDP complex and is inactivated by heparin-AT III. However, as successive fibrin layers are removed, inaccessible molecules of thrombin are exposed at the surface of the residual clot, possibly contributing to the occurrence during thrombolytic the...